Breaking News

Hoth Therapeutics, WuXi STA Sign API and Drug Product Contracts

WuXi STA to provide process development and manufacturing of the API and formulation of drug product for HT-KIT.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Hoth Therapeutics, Inc., a biopharmaceutical company, has entered into contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing of the active pharmaceutical ingredient (API) and formulation of drug product for the continued development and commercialization of HT-KIT.   HT-KIT is a new molecular entity morpholino oligonucleotide therapy in development for targeting mast cell-derived cancers (aggressive systemic mastocytosis (ASM), sys...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters